Cardax Inc (OTCQB:CDXI), a development stage biopharmaceutical company, has announced its financial results for the first quarter of 2020, it was reported on Friday.
The company reported net losses of USD1,002,868 in the first quarter of 2020 compared to a loss of USD1,135,420 in the year-ago period.
The firm raised USD770,000 through the issuance of convertible notes in the first quarter of 2020. Out of USD770,000, USD150,000 was used to pay off a convertible note due in March 2020, with the balance used for general working capital.
The Company believes that its operations, including revenues and any public or private offerings, may be affected in 2020 by the COVID-19 pandemic, although the extent of the impact is uncertain at this time.
West Pharmaceutical Services declares quarterly dividend of USD0.22 per share
MedPal AI acquires eMARx to expand digital care home platform
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
Labcorp declares quarterly dividend of USD0.72 per share
Aptamer Group launches Optimer-based Ebola diagnostic programme
SK bioscience to lead Gates Foundation-funded ROTOR project
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases
Lilly declares Q3 2026 dividend
Abbott declares quarterly dividend of USD0.63 per share
Gilead Sciences mobilises remdesivir donation to support Ebola response in Uganda
INOVIO's oartner ApolloBio reports positive topline results from Phase 3 trial of VGX-3100
Lilly declares Q2 2026 dividend
Collegium to acquire AZSTARYS from Corium Therapeutics
CVS Health announces quarterly dividend of USD0.665 per share
Convatec launches co-branded eakin freeseal ostomy seal in North America